Akcje Astrazeneca plc (AZN) — czy to dobra firma?

Akcje Astrazeneca plc (AZN) — czy to dobra firma? — InspectStocks

Jak zarabia

Sales of prescription medicines
Revenue from medicine partnerships

Konkuruje z

Co sprzedaje6

Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.

Pokaż 3 więcej

Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.

Kto to kupuje3

Patients receive the medicines, usually after a clinician prescribes them.
Hospitals, clinics and pharmacies purchase or dispense medicines for patients.
Government health systems and private insurers may pay for or reimburse medicines.

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

1Sales of many medicines depend on patents and other protections that limit competing generic or biosimilar versions.
2Some medicines are developed or commercialised with partners, so their sales and revenue depend partly on those arrangements.
3Sales in China are affected by government volume-based purchasing and reimbursement decisions.

Co może pójść nie tak

1Generic competition can reduce sales when patents expire or competitors enter early; the company reported generic entry affecting Farxiga and Brilinta.
2Clinical trials can fail to show that a medicine works, as occurred in the Wainua heart-disease trial discussed on the latest earnings call.
3Government purchasing and reimbursement rules, including China’s volume-based procurement, can affect medicine prices and sales.

Pełne sprawozdania finansowe →

O spółce Astrazeneca plc

AstraZeneca develops, makes and sells prescription medicines. Its medicines treat several types of cancer, heart and kidney conditions, breathing and immune disorders, and rare diseases. It also works with other drug companies to develop and sell some medicines, sharing revenue from those partnerships.

Siedziba: Cambridge, England, United Kingdom
Rok założenia: 1992
Notowana na: New York Stock Exchange
Koniec roku obrotowego: December 31

Zbudowane z własnych raportów spółki Astrazeneca plc składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.

Keep exploring

The themes Astrazeneca is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.

The theme it is part of

Highest-graded in Drug Manufacturers General

Graded A or B and worth $2B or more: A first, then the largest.

All 19 graded companies in its industry

Grade rose recently in Healthcare

Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.

All grade rises

Jak zarabia

Sales of prescription medicines
Revenue from medicine partnerships

Konkuruje z

Co sprzedaje6

Tagrisso
A prescription medicine for certain lung cancers with changes in the epidermal growth factor receptor gene.
Imfinzi
An immune-system treatment used for several cancers, including lung, bladder, liver and stomach cancers.
Farxiga/Forxiga
A tablet used for type 2 diabetes, heart failure and chronic kidney disease.

Pokaż 3 więcej

Ultomiris
A long-acting medicine for rare diseases in which the immune system damages blood cells or other tissues.
Fasenra
An injected medicine for severe asthma and certain other conditions involving high levels of eosinophils, a type of white blood cell.
Enhertu
A targeted cancer medicine for cancers with high or altered levels of human epidermal growth factor receptor 2.

Kto to kupuje3

Patients receive the medicines, usually after a clinician prescribes them.
Hospitals, clinics and pharmacies purchase or dispense medicines for patients.
Government health systems and private insurers may pay for or reimburse medicines.

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

1Sales of many medicines depend on patents and other protections that limit competing generic or biosimilar versions.
2Some medicines are developed or commercialised with partners, so their sales and revenue depend partly on those arrangements.
3Sales in China are affected by government volume-based purchasing and reimbursement decisions.

Co może pójść nie tak

1Generic competition can reduce sales when patents expire or competitors enter early; the company reported generic entry affecting Farxiga and Brilinta.
2Clinical trials can fail to show that a medicine works, as occurred in the Wainua heart-disease trial discussed on the latest earnings call.
3Government purchasing and reimbursement rules, including China’s volume-based procurement, can affect medicine prices and sales.

Pełne sprawozdania finansowe →

O spółce Astrazeneca plc

Siedziba: Cambridge, England, United Kingdom
Rok założenia: 1992
Notowana na: New York Stock Exchange
Koniec roku obrotowego: December 31

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje3

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Astrazeneca plc

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje3

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Astrazeneca plc

Astrazeneca plc

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Wzrost i gotówka — 5 z 5

Trend biznesu

Cena akcji i ocena w czasie

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje3

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Astrazeneca plc

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Jak zarabia

Konkuruje z

Co sprzedaje6

Kto to kupuje3

Na czym się opiera i co może to zburzyć

Od czego zależy ta działalność

Co może pójść nie tak

O spółce Astrazeneca plc

Astrazeneca plc

Wyniki historyczne

Keep exploring

The theme it is part of

Highest-graded in Drug Manufacturers General

Grade rose recently in Healthcare

Big pharma

Wzrost i gotówka — 5 z 5

Trend biznesu

Cena akcji i ocena w czasie